Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSE-COV
PACTR202007720062393Phase 2Not yet recruiting
- Sponsor
- ANRS
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Lopinavir + ritonavir, Lopinavir + ritonavir + telmisartan and Lopinavir + ritonavir + atorvastatin (3 arms). Primary endpoint: Virologic and inflammatory response at Day 11. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
lopinavirritonavirtelmisartanatorvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202007720062393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007720062393.